Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.38 |
| ▸ | CDK2 | P24941 | 9/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359626 | 0.89 | CCNA2 (0.42) | CCNA2CDK2CCNA1HDAC1HDAC2 | |
| SCHEMBL20155196 | 0.85 | CCNA2 (0.41) | CCNA2CDK2CCNA1HDAC1HDAC2 | |
| SCHEMBL20155193 | 0.81 | PAK1 (0.39) | CCNA2CDK2CCNA1HDAC1HDAC2 | |
| SCHEMBL19359631 | 0.81 | PAK1 (0.39) | CCNA2CDK2CCNA1HDAC1HDAC2 | |
| SCHEMBL22313392 | 0.81 | ADORA1 (0.48) | CCNA2CDK2CCNA1EPHX2MERTK | |
| SCHEMBL23393876 | 0.78 | HDAC6 (0.42) | HDAC1HDAC2HDAC6HDAC3EPHX2 | |
| SCHEMBL22313895 | 0.78 | HDAC6 (0.42) | HDAC1HDAC2HDAC6HDAC3EPHX2 | |
| SCHEMBL19359625 | 0.78 | HDAC6 (0.42) | HDAC1HDAC2HDAC6HDAC3EPHX2 | |
| SCHEMBL23393877 | 0.76 | HDAC6 (0.37) | HDAC1HDAC2HDAC6HDAC3EPHX2 | |
| SCHEMBL19359660 | 0.72 | CTSK (0.45) | CCNA2CDK2CCNA1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200247810-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247810-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | CCNA2 73/4885CDK2 27/4885CCNA1 79/4885 |
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | CCNA2 73/4885CDK2 27/4885CCNA1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.